The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma

Clinical trial NCT04997850 · COMPLETED

Trial details

NCT number

NCT04997850

Sponsor

Xinrui Zhu，MD

Status

COMPLETED

Phase

Phase 1, Phase 2

Study type

INTERVENTIONAL

Start date

2020-10-01

Primary completion

2022-05-24

Enrollment

142

View on ClinicalTrials.gov